PRDX6 attenuates oxidative stress-and TGF-induced abnormalities of human trabecular meshwork cells

Free Radical Research

Volumn 43, Issue 9, 2009, Pages 783-795

  Fatma, Nigar ^a   Kubo, Eri ^b   Toris, Carol B ^a   Stamer, W D ^c   Camras, Carl B ^a   Singh, Dhirendra P ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF FUKUI   (Japan)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Antioxidant; Extracellular matrix proteins; Peroxiredoxin 6; Reactive oxygen species; Transforming growth factor

Indexed keywords

GELATINASE A; MESSENGER RNA; PEROXIREDOXIN 6; REACTIVE OXYGEN METABOLITE; SCLEROPROTEIN; THROMBOSPONDIN 1; TRANSFORMING GROWTH FACTOR BETA; ACTIN; BETAIG H3 PROTEIN; BETAIG-H3 PROTEIN; FIBRONECTIN; GUANINE NUCLEOTIDE BINDING PROTEIN; HYBRID PROTEIN; HYDROGEN PEROXIDE; MMP2 PROTEIN, HUMAN; OXIDIZING AGENT; PLASMINOGEN ACTIVATOR INHIBITOR 1; PRDX6 PROTEIN, HUMAN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; SERPINE1 PROTEIN, HUMAN; TPM1 PROTEIN, HUMAN; TPM2 PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TROPOMYOSIN;

ARTICLE; BIOCHEMISTRY; CLINICAL FEATURE; CONTROLLED STUDY; GLAUCOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; TRABECULAR MESHWORK; CELL AGING; CELL CULTURE; DNA DAMAGE; DOSE RESPONSE; DRUG EFFECT; GENETIC TRANSDUCTION; GENETICS; METABOLISM; PATHOLOGY; PHENOTYPE;

ACTINS; CELL AGING; CELLS, CULTURED; DNA DAMAGE; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTRACELLULAR MATRIX PROTEINS; FIBRONECTINS; GLAUCOMA; GTP-BINDING PROTEINS; HUMANS; HYDROGEN PEROXIDE; MATRIX METALLOPROTEINASE 2; OXIDANTS; OXIDATIVE STRESS; PEROXIREDOXIN VI; PHENOTYPE; PLASMINOGEN ACTIVATOR INHIBITOR 1; REACTIVE OXYGEN SPECIES; RECOMBINANT FUSION PROTEINS; RNA, MESSENGER; THROMBOSPONDIN 1; TRABECULAR MESHWORK; TRANSDUCTION, GENETIC; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSGLUTAMINASES; TROPOMYOSIN;

EID: 70349325832     PISSN: 10715762     EISSN: 10292470     Source Type: Journal    
DOI: 10.1080/10715760903062887     Document Type: Article

References (55)

1. Chong ZZ, Li F, Maiese K. Oxidative stress in the brain: novel cellular targets that govern survival during neurodegenerative disease. Prog Neurobiol 2005;75:207-246.
2. He Y, Leung KW, Zhang YH, Duan S, Zhong XF, Jiang RZ, Peng Z, Tombran-Tink J, Ge J. Mitochondrial complex I defect induces ROS release and degeneration in trabecular meshwork cells of POAG patients: protection by antioxidants. Invest Ophthalmol Vis Sci 2008;49:1447-1458.
3. Fatma N, Kubo E, Sharma P, Beier DR, Singh DP. Impaired homeostasis and phenotypic abnormalities in Prdx6-/-mice lens epithelial cells by reactive oxygen species: increased expression and activation of TGFbeta. Cell Death Differ 2005;12:734-750.
4. Azhar S, Cao L, Reaven E. Alteration of the adrenal antioxidant defense system during aging in rats. J Clin Invest 1995;96:1414-1424.
5. Wang X, Phelan SA, Forsman-Semb K, Taylor EF, Petros C, Brown A, Lerner CP, Paigen B. Mice with targeted mutation of peroxiredoxin 6 develop normally but are susceptible to oxidative stress. J Biol Chem 2003;278:25179-25190.
6. Barcellos-Hoff MH, Dix TA. Redox-mediated activation of latent transforming growth factor-beta 1. Mol Endocrinol 1996;10:1077-1083.
7. Kubo E, Fatma N, Akagi Y, Beier DR, Singh SP, Singh DP. TAT-mediated PRDX6 protein transduction protects against eye lens epithelial cell death and delays lens opacity. Am J Physiol Cell Physiol 2008;294:C842-C855.
8. Fatma N, Kubo E, Sen M, Agarwal N, Thoreson WB, Camras CB, Singh DP. Peroxiredoxin 6 delivery attenuates TNF-alpha-and glutamate-induced retinal ganglion cell death by limiting ROS levels and maintaining Ca(2 + ) homeostasis. Brain Res 2008;1233:63-78.
9. Fleenor DL, Shepard AR, Hellberg PE, Jacobson N, Pang IH, Clark AF TGFbeta2-induced changes in human trabecular meshwork: implications for intraocular pressure. Invest Ophthalmol Vis Sci 2006;47:226-234.
10. Sacca SC, Pascotto A, Camicione P, Capris P, Izzotti A. Oxidative DNA damage in the human trabecular meshwork: clinical correlation in patients with primary open-angle glaucoma. Arch Ophthalmol 2005;123:458-463
11. Sacca SC, Izzotti A, Rossi P, Traverso C. Glaucomatous outflow pathway and oxidative stress. Exp Eye Res 2007;84:389-399.
12. Moreno MC, Campanelli J, Sande P, Sanez DA, Keller Sarmiento MI, Rosenstein RE. Retinal oxidative stress induced by high intraocular pressure. Free Radic Biol Med 2004;37:803-812.
13. Izzotti A, Bagnis A, Sacca SC. The role of oxidative stress in glaucoma. Mutat Res 2006;612:105-114.
14. Ohia SE, Opere CA, Leday AM. Pharmacological consequences of oxidative stress in ocular tissues. Mutat Res 2005;579:22-36.
15. Tamm ER, Fuchshofer R. What increases outflow resistance in primary open-angle glaucoma? Surv Ophthalmol 2007;52:S101-S104.
16. Jampel HD, Roche N, Stark WJ, Roberts AB. Transforming growth factor-beta in human aqueous humor. Curr Eye Res 1990;9:963-969.
17. Baleriola J, Garćia-Feijoo J, Mart́inez-de-la-Casa JM, Fernandez-Cruz A, de la Rosa EJ, Fernandez-Durango R. Apoptosis in the trabecular meshwork of glaucomatous patients. Mol Vis 2008;14:1513-1516.
18. Izzotti A, Sacca SC, Cartiglia C, De Flora S. Oxidative deoxyribonucleic acid damage in the eyes of glaucoma patients. Am J Med 2003;114:638-646.
19. Sacca SC, Izzotti A. Oxidative stress and glaucoma: injury in the anterior segment of the eye. Prog Brain Res 2008;173:385-407
20. Lutjen-Drecoll E. Morphological changes in glaucomatous eyes and the role of TGFbeta2 for the pathogenesis of the disease. Exp Eye Res 2005;81:1-.
21. Wordinger RJ, Fleenor DL, Hellberg PE, Pang IH, Tovar TO, Zode GS, Fuller JA, Clark AF. Effects of TGF-beta2, BMP-4, and gremlin in the trabecular meshwork: implications for glaucoma. Invest Ophthalmol Vis Sci 2007;48:1191-1200.
22. Zhao X, Ramsey KE, Stephan DA, Russell P. Gene and protein expression changes in human trabecular meshwork cells treated with transforming growth factor-beta. Invest Ophthalmol Vis Sci 2004;45:4023-4034.
23. Fuchshofer R, Yu AH, Welge-Lüssen U, Tamm ER. Bone morphogenetic protein-7 is an antagonist of transforming growth factor-beta2 in human trabecular meshwork cells. Invest Ophthalmol Vis Sci 2007;48:715-726.
24. Manevich Y, Fisher AB. Peroxiredoxin 6, a 1-Cys peroxiredoxin, functions in antioxidant defense and lung phospholipid metabolism. Free Radic Biol Med 2005;238:1422-1432.
25. Fatma N, Singh DP, Shinohara T, Chylack LT Jr. Transcriptional regulation of the antioxidant protein 2 gene, a thiol-specific antioxidant, by lens epithelium-derived growth factor to protect cells from oxidative stress. J Biol Chem 2001;276:48899-48907
26. Nagahara H, Vocero-Akbani AM, Snyder EL, Ho A, Latham DG, Lissy NA, Becker-Hapak M, Ezhevsky SA, Dowdy SF. Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration. Nat Med 1998;4:1449-1452.
27. Stamer DW, Roberts BC, Epstein DL, Allingham RR. Isolation of primary open-angle glaucomatous trabecular meshwork cells from whole eye tissue. Curr Eye Res 2000;20:347-350.
28. Kubo E, Miyazawa T, Fatma N, Akagi Y, Singh DP. Development-and age-associated expression pattern of peroxiredoxin 6, and its regulation in murine ocular lens. Mech Ageing Dev 2006;127:249-256.
29. Manevich Y, Sweitzer T, Pak JH, Feinstein SI, Muzykantov V, Fisher AB. 1-Cys peroxiredoxin overexpression protects cells against phospholipid peroxidation-mediated membrane damage. Proc Natl Acad Sci USA 2002;99:11599-11604.
30. Acott TS, Kelley MJ. Extracellular matrix in the trabecular meshwork. Exp Eye Res 2008;86:543-561.
31. Keller KE, Aga M, Bradley JM, Kelley MJ, Acott TS. Extracellular matrix turnover and outflow resistance. Exp Eye Res 2009;88:676-682.
32. Gallagher BM, Phelan SA. Investigating transcriptional regulation of Prdx6 in mouse liver cells. Free Radic Biol Med 2007;42:1270-1277.
33. Flügel-Koch C, Ohlmann A, Fuchshofer R, Welge-Lüssen U, Tamm ER. Thrombospondin-1 in the trabecular meshwork: localization in normal and glaucomatous eyes, and induction by TGF-beta1 and dexamethasone in vitro. Exp Eye Res 2004;79:649-663.
34. Murphy-Ullrich JE, Poczatek M. Activation of latent TGF-beta by thrombospondin-1: mechanisms and physiology. Cytokine Growth Factor Rev 2000;11:59-69.
35. Tane N, Dhar S, Roy S, Pinheiro A, Ohira A, Roy S. Effect of excess synthesis of extracellular matrix components by trabecular meshwork cells: possible consequence on aqueous outflow. Exp Eye Res 2007;84:832-842.
36. Tovar-Vidales T, Roque R, Clark AF, Wordinger RJ. Tissue transglutaminase expression and activity in normal and glaucomatous human trabecular meshwork cells and tissues. Invest Ophthalmol Vis Sci 2008;49:622-628.
37. Oh DJ, Martin JL, Williams AJ, Russell P, Birk DE, Rhee DJ. Effect of latanoprost on the expression of matrix metallopro-teinases and their tissue inhibitors in human trabecular meshwork cells. Invest Ophthalmol Vis Sci 2006;47: 3887-3895.
38. Pang IH, Hellberg PE, Fleenor DL, Jacobson N, Clark AF. Expression of matrix metalloproteinases and their inhibitors in human trabecular meshwork cells. Invest Ophthalmol Vis Sci 2003;44:3485-3493.
39. Ronkko S, Rekonen P, Kaarniranta K, Puustjarvi T, Terasvirta M, Uusitalo H. Matrix metalloproteinases and their inhibitors in the chamber angle of normal eyes and patients with primary open-angle glaucoma and exfoliation glaucoma. Graefes Arch Clin Exp Ophthalmol 2007; 245:697-704. (Pubitemid 46951236)
40. Clark AF. New discoveries on the roles of matrix metalloproteinases in ocular cell biology and pathology. Invest Ophthalmol Vis Sci 1998;39:2514-2516.
41. Eitzman DT, Ginsburg D. Of mice and men. The function of plasminogen activator inhibitors (PAIs) in vivo. Adv Exp Med Biol 1997;425:131-141.
42. Bakin AV, Safina A, Rinehart C, Daroqui C, Darbary H, Helfman DM. A critical role of tropomyosins in TGF-beta regulation of the actin cytoskeleton and cell motility in epithelial cells. Mol Biol Cell 2004;15:4682-4694
43. Sakai H, Park BC, Shen X, Yue BY. Transduction of TAT fusion proteins into the human and bovine trabecular meshwork. Invest Ophthalmol Vis Sci 2006;47:4427-4434.
44. Zhou L, Li Y, Yue BY. Oxidative stress affects cytoskeletal structure and cell-matrix interactions in cells from an ocular tissue: the trabecular meshwork. J Cell Physiol 1999;180 182-189. (Pubitemid 29297195)
45. Yamazaki Y, Matsunaga H, Nishikawa M, Ando A, Kaneko S, Okuda K, Wada M, Ito S, Matsumura M. Senescence in cultured trabecular meshwork cells. Br J Ophthalmol 2007;91:808-811.
46. Caballero M, Liton PB, Challa P, Epstein DL, Gonzalez P. Effects of donor age on proteasome activity and senescence in trabecular meshwork cells. Biochem Biophys Res Commun 2004;323:1048-1054.
47. Halliwell B. Free radicals, reactive oxygen species and human disease: a critical evaluation with special reference to atherosclerosis. Br J Exp Pathol 1989;70:737-757.
48. Fisher AB. Redox signaling across cell membranes. Antioxid Redox Signal 2008; Dec 8. [Epub ahead of print].
49. Caballero M, Liton PB, Epstein DL, Gonzalez P. Proteasome inhibition by chronic oxidative stress in human trabecular meshwork cells. Biochem Biophys Res Commun 2003;308: 346-352
50. Faralli JA, Schwinn MK, Gonzalez JM Jr, Filla MS, Peters DM. Functional properties of fibronectin in the trabecular meshwork. Exp. Eye Res 2009;88:689-693.
51. Campisi J. Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell 2005;120:513-522.
52. Passos JF, Von Zglinicki T Oxygen free radicals in cell senescence: are they signal transducers? Free Radic Res 2006;40:1277-1283.
53. Liton PB, Challa P, Stinnett S, Luna C, Epstein DL, Gonzalez P. Cellular senescence in the glaucomatous outflow pathway. Exp Gerontol 2005;40:745-748.
54. Luna C, Li G, Liton PB, Qiu J, Epstein DL, Challa P, Gonzalez P. Resveratrol prevents the expression of glaucoma markers induced by chronic oxidative stress in trabecular meshwork cells. Food Chem Toxicol 2009;47:198-204.
55. Yu AL, Fuchshofer R, Kampik A, Welge-Lüssen U. Effects of oxidative stress in trabecular meshwork cells are reduced by prostaglandin analogues. Invest Ophthalmol Vis Sci 2008;49:4872-4880